Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
9 March 2017
Header
Header image
News

News

Mutual Recognition Agreement (MRA) on Good Manufacturing Practices (GMP) heralds the end of duplicative inspections and better use of resources
09 March 2017

EFPIA welcomes the announcement of the adoption of an updated EU-US Mutual Recognition Agreement (MRA) on Good Manufacturing Practices (GMP) inspections.    Implementation of the MRA [...] Read more

News

EBE, EFPIA and IFPMA have today launched a position paper entitled “Considerations for physicians on switching decisions regarding biosimilars”
09 March 2017

Switching describes a physician's decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to [...] Read more

Events calendar

Events Calendar

China/EU Pharmaceutical Industry Forum, Joint Workshop
On 17/05/2017 (Shanghai)

EFPIA and CPIA are organising jointly a China/EU Pharmaceutical Industry Forum on Wednesday, 17 May 2017, in Shanghai, China. It is now possible to register for the workshop by filling in this form and sending it to Sandra Rodrigues (sandra.rodrigues@efpia.eu) ASAP, but not later than 24 April 2017. 

The workshop covers 4 different themes, namely: Pharmaceuticals in the Environment; the Drug Administration Law (DAL) revision; Coding and Serialisation; and Compliance (marketing ethics).

The preliminary agenda can be downloaded here.
 
Read more

Events Calendar

DIA BioVenture Day
On 28/03/2017 (Glasgow, UK)

DIA is excited to convene its 1st BioVenture Day, in a unique format with the participation of a very broad set of senior healthcare stakeholders. You will be able to explore whether the current BioVenture paradigm is delivering returns for patients, investors, and the healthcare system.

Read more

Events Calendar

DIA EuroMeeting 2017
From 29/03/2017 to 31/03/2017 (Glasgow, UK)

The DIA EuroMeeting 2017 is unique in presenting the entire healthcare microcosm, ranging from policy and regulations, to R&D marketing and access.

In an intense and stimulating three days, you will enjoy learning and debating. You will meet not only people you know, but also those that you want to know and those that you should know.

The DIA EuroMeeting allows you to debate the issues across the entire drug development value chain during the conference, and find solutions within the exhibition with 2,500+ other cross-functional thought leaders.

You will hear the latest solutions and challenges in healthcare. You will have plenty of opportunities to network and build relationships with trend-setters in e.g. the areas of regulatory science, clinical research and operations, value demonstration leads and patient advocates. The resulting knowledge transfer and lasting partnerships will reduce the burden of regulatory barriers, benefiting your business now and further down the line.

Read more

Events Calendar

13th Annual Meeting of ISMPP - Global Publication Practices: Advancing Ethics and Scientific Integrity in an Era of Data-Sharing
From 01/05/2017 to 03/05/2017 (National Harbor, Maryland, USA)

This year’s theme and session topics highlight the ever-expanding area of data sharing. The debate about data sharing has shifted from “should we?” to “how do we?” This is a time when ethics and scientific integrity are even more critical as data sharing connects researchers more closely and global requirements begin to emerge.

The aim of the 13th Annual Meeting of ISMPP is to:

• Understand recent developments in key areas such as data sharing, peer-review, and payer requirements
• Enable medical publication professionals to positively impact publication practices across global markets
• Extend learning opportunities on innovative ways to work smarter and faster at the speed of business

Read more

Documents

From our blog

Considerations for physicians on switching decisions regarding biosimilars
09 March 2017 (Position Papers)

Switching describes the medical practice of a physician deciding to exchange the product that a patient receives for another product. The practice of a physician [...] Read more

What we are reading

What we are reading

The IMI programmes driving access to innovative medicines
09 March 2017 (Adjacent Open Access)

By providing the infrastructure to support drug discovery, the IMI is accelerating access to innovative medicines, as the EFPIA highlights here

Read more

What we are reading

UK children with cancer could miss out on drug trials after Brexit, doctors warn
09 March 2017 (The Guardian)

Fears youngsters could be denied access to Europe-wide tests of new medicines when Britain leaves EU amid calls for reform

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail